What is your preferred steroid sparing agent in the treatment of Sjögren associated LIP?

There is unfortunately very limited data comparing the efficacy of various steroid-sparing agents for the treatment of connective tissue disease-related ILD, and no large prospective studies have specifically addressed the ideal approach for patients with underlying Sjogrens. Mycophenolate and azathioprine remain the two first-line therapies for CTD-ILD and are generally considered to be equally efficacious. However, my personal experience and trends in the literature suggest that mycophenolate ...

Consensus guidelines for pulmonary manifestations in SjD provide some guidance. Lee et al., PMID 33075377

For LIP with lymphocytic predominance, some would favor early consideration of rituximab.

The treatment algorithm in the publication for the spectrum of ILD in SjD is included in the publication.